Skip to content

This website uses cookies to understand how visitors use the site. No personal data is sold or shared. See our Privacy Notice.

About Eloxx Careers

Science Publications

Pipeline Overview

Clinical Trials

EXACT Study — Alport Syndrome

In Planning

ADPKD Clinical Study

Nonsense Mutation Alport Syndrome Nonsense Mutation ADPKD

Overview

Investor Overview

News & Events

Press Releases Events & Conferences

Governance & Stock

Stock Information Documents & Charters SEC Filings

IR Resources

Email Alerts & FAQs Contact Us

About

About Eloxx Careers

Our Approach

Science Publications

Pipeline

Pipeline Overview EXACT Study — Alport Syndrome ADPKD Clinical Study

People living with kidney disease

Nonsense Mutation Alport Syndrome Nonsense Mutation ADPKD

Investors & Media

Investor Relations Press Releases Events & Conferences Stock Information Governance SEC Filings Email Alerts Contact

← All press releases

Alport Syndrome Natural History from the RaDaR registry: Associations with gene, variant type and sex

June 21, 2023

Eloxx Pharmaceuticals is a clinical-stage company developing exaluren — an investigational therapy for people with Alport syndrome and ADPKD caused by nonsense mutations.

Our Approach

Science Publications Pipeline EXACT Study

Patients

Nonsense Mutation Alport Syndrome Nonsense Mutation ADPKD

Company

About Eloxx Careers Investors & Media Contact Us

© 2026 Eloxx Pharmaceuticals, Inc. All rights reserved. Privacy Notice · Terms of Use Exaluren is an investigational compound and has not been approved by the FDA or any regulatory authority. This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.